Obezite, Diabetes Mellitus ve Hiperlipideminin Lipom Gelişimi Üzerinde Etkisinin Değerlendirilmesi. Obezite Lipom Boyutunu Etkiler mi?

Abstract

Amaç: Bu çalışmada obez, diabetes mellitus (DM), hiperlipidemisi olan hastalardaki lipomlar ile normal vücut kütle indeksine (VKİ) sahip, normal seviyelerde kan lipid düzeyleri bulunan ve DM bulunmayan bireylerdeki lipomlar arasındaki klinikopatolojik özellikleri incelemeyi amaçladık. Gereç ve Yöntemler: Bölümümüzde 2017- 2021 yılları arasında tanı alan lipom olgularına ait klinikopatolojik veriler retrospektif olarak hasta dosyaları taranarak incelenmiştir. DM, hiperlipidemi ve obez olan bireyler ayrı ayrı belirlenmiştir. Her bir lipoma ait tümör çapı, tümör sayısı (tek ya da multiple (çok sayıda)) ve tümör histolojik alt tipi (sıradan veya varyant lipom) arşiv patoloji raporları taranarak belirlenmiştir. Obezite, DM ve hiperlipidemisi olan ve olmayan bireylerdeki lipomlar bu histolojik özellikler açısından karşılaştırılmıştır. Bulgular: Çalışmamızda DM ve hiperlipidemisi bulunan veya bulunmayan bireyler arasında lipom boyutu, lipom sayısı ve tümör histolojik alt tipi bakımından anlamlı farklılık bulunmamıştır. Obezite olan bireylerde tümör çapları olmayanlara göre daha yüksek bulunmasına rağmen bu farklılık istatistiksel olarak anlamlı değildir (p=0,825). Çalışmamızda dikkat çekici bir nokta VKİ en yüksek olan bireyde en büyük tümör çapının bulunmasıdır. Tümör çapları bizim serimizde 40 yaş üstü bireylerde anlamlı olarak daha büyük saptanmıştır (p=0,03). Sonuç: Sonuç olarak obezitenin lipom gelişimi yanı sıra lipom boyutu üzerinde de etkili olabileceğini ve hatta eşlik eden DM, hiperlipideminin tümör boyutunu daha da artırabileceğini düşünüyoruz.

Keywords

• Obezite
• diabetes mellitus
• lipom
• tümör boyutu

Evaluation of the Effect of Obesity, Diabetes Mellitus and Hyperlipidemia on the Development of Lipoma. Does Obesity Affect Lipoma Size?

Abstract

Aim: In this study, we aimed to examine the clinicopathological features of lipomas between patients with obesity, diabetes mellitus (DM), hyperlipidemia and individuals with normal body mass index, normal blood lipid levels and without DM. Material and Methods: Lipomas that were diagnosed between 2017 and 2021 in our department were retrospectively reviewed for clinicopathological datas. Individuals with DM, hyperlipidemia and obesity were determined. Diameter, number (single or multiple) and histological subtype (ordinary or variant lipoma) of each lipoma were determined by scanning archival pathology reports. Lipomas in individuals with and without obesity, DM, and hyperlipidemia were compared for these histological features. Results: In our study, no significant difference was found between individuals with or without DM and hyperlipidemia in terms of lipoma size, number and histological subtype. Although tumor diameters were found to be higher in obese individuals than in nonobeses, this difference was not statistically significant (p=0.825). A remarkable point in our study was that the largest tumor diameter was found in the individual with the highest body mass index. Also tumor diameters were found to be significantly larger in individuals over 40 years of age in our series (p=0.03). Conclusion: In conclusion, we think that obesity may have an effect on lipoma size as well as lipoma development, and even concomitant DM and hyperlipidemia may increase tumor size even more.

Keywords

• obesity
• diabetes mellitus
• lipoma
• tumor size

References

1. 1. Kolb L, Yarrarapu SNS, Ameer MA, Rosario-Collazo JA. Lipoma. 2021 Mar 18. In: StatPearls (https://www.ncbi.nlm. nih.gov/books/NBK507906/, Erişim Tarihi:23.01.2022).
2. 2. Chrisinger JSA. Update on Lipomatous Tumors with Emphasis on Emerging Entities, Unusual Anatomic Sites, and Variant Histologic Patterns. Surg Pathol Clin. 2019;12(1):21-33.
3. 3. Charifa A, Azmat CE, Badri T. Lipoma Pathology. 2020 Sep 21. In: StatPearls [Internet].
4. 4. Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, Ono SJ. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem. 2000;275(19):14394-14400.
5. 5. Tsatsoulis A, Paschou SA. Metabolically healthy obesity: Criteria, epidemiology, controversies, and consequences. Curr Obes Rep. 2020;9(2):109-120.
6. 6. Aust MC, Spies M, Kall S, Jokuszies A, Gohritz A, Vogt P. Posttraumatic lipoma: Fact or fiction? Skinmed. 2007;6(6):266- 270.
7. 7. Gallagher EJ, LeRoith D. Obesity and diabetes: The increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95(3):727-748.
8. 8. Panagopoulos I, Gorunova L, Agostini A, Lobmaier I, Bjerkehagen B, Heim S. Fusion of the HMGA2 and C9orf92 genes in myolipoma with t(9;12)(p22;q14). Diagn Pathol. 2016;11:22.

9. 9. Fletcher CD, Akerman M, Dal Cin P, de Wever I, Mandahl N, Mertens F, Mitelman F, Rosai J, Rydholm A, Sciot R, Tallini G, van den Berghe H, van de Ven W, Vanni R, Willen H. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol. 1996;148(2):623-630.
10. 10. Schepens Eye Research Institute. “Obesity Gene” Causes Cancer Of Fat Tissue, Schepens Scientists Find.” ScienceDaily. ScienceDaily, 2000 April.
11. 11. Le Duc D, Lin CC, Popkova Y, Yang Z, Akhil V, Çakir MV, Grunewald S, Simon JC, Dietz A, Dannenberger D, Garten A, Lemke JR, Schiller J, Blüher M, Nono Nankam PA, Rolle- Kampczyk U, von Bergen M, Kelso J, Schöneberg T. Reduced lipolysis in lipoma phenocopies lipid accumulation in obesity. Int J Obes (Lond). 2021;45(3):565-576.
12. 12. Lemaitre M, Chevalier B, Jannin A, Bourry J, Espiard S, Vantyghem MC. Multiple symmetric and multiple familial lipomatosis. Presse Med. 2021;50(3):104077
13. 13. Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Péoc’h M, Istier L, Chalabreysse P, Muller C, Alberti L, Bringuier PP, Scoazec JY, Schott AM, Bergeron C, Cellier D, Blay JY, Ray-Coquard I. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6(8):e20294.
14. 14. Fallahian F, Ardestani A, Pranckevicius E, Raut CP, Tavakkoli A, Sheu EG. The impact of lipomatous tumors on type 2 diabetes: Are adipose-derived tumors metabolically active? J Surg Res. 2018;222:48-54.
15. 15. Self TH, Akins D. Dramatic reduction in lipoma associated with statin therapy. J Am Acad Dermatol. 2008;58(2 Suppl):30-31.
16. 16. Dawoud NM, Bakry OA, Seleit I. Homozygous Familial Hypercholesterolemia associated with symmetric subcutaneous lipomatosis. Indian J Dermatol. 2015;60(4):420.
17. 17. Allen B, Rader C, Babigian A. Giant lipomas of the upper extremity. Can J Plast Surg. 2007;15(3):141-144.